Johnson & Johnson’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Johnson & Johnson’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,200	Closed	-$36.1K	–	23
2024 Q1	$36.1K	Hold	4,200	–	–	﹤0.01%	21
2023 Q4	$14.7K	Hold	4,200	–	–	﹤0.01%	22
2023 Q3	$15K	Hold	4,200	–	–	0.01%	24
2023 Q2	$24.4K	Hold	4,200	–	–	0.01%	21
2023 Q1	$159K	Hold	4,200	–	–	0.05%	20
2022 Q4	$125K	Hold	4,200	–	–	0.04%	19
2022 Q3	$140K	Hold	4,200	–	–	0.04%	19
2022 Q2	$168K	Hold	4,200	–	–	0.04%	19
2022 Q1	$221K	Hold	4,200	–	–	0.04%	19
2021 Q4	$233K	Hold	4,200	–	–	0.03%	20
2021 Q3	$325K	Buy	+4,200	New	+$356K	0.03%	20

Other funds holding TCON

GPFA

Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return

Johnson & Johnson's TCON Position: Q2 2024 in Review

Johnson & Johnson sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 4,200 shares — an estimated $36.1K sold.

Johnson & Johnson first reported a position in TCON in Q3 2021 and held it in 11 quarters. The position peaked at $325K in Q3 2021. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

Johnson & Johnson reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Johnson & Johnson sold 4,200 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $36.1K.
Johnson & Johnson first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 11 quarters.
Johnson & Johnson's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $325K in Q3 2021.
1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Johnson & Johnson's 13F filing for Q2 2024, filed 9 Aug 2024.